C
ontraction in skeletal and cardiac muscles is triggered by the binding of Ca 2ϩ to the troponin C (TnC) component of the troponin complex (1, 2) . TnC, like other members of the calmodulin (CaM) superfamily, consists of two lobes joined by a flexible central linker (see Fig. 1 A legend). The C-terminal or ''structural'' lobe (C-lobe) comprises two EF-hand motifs (domains III and IV) that bind either Ca . Domain I is nonfunctional because of the mutation of Ca 2ϩ ligands (D29L, D31A) and a V28 insertion. The other two subunits of troponin are troponin I (TnI), which binds to F-actin and inhibits actomyosin ATPase, and troponin T (TnT), which links TnC and TnI to tropomyosin. In the relaxed state of muscle, the interaction between myosin and F-actin is blocked by tropomyosin, whose position on F-actin is determined by its linkage with troponin. The binding of Ca 2ϩ to the N-lobe of TnC produces a structural change so that TnC interacts strongly with TnI. As a result TnI is released from actin, and tropomyosin moves from its blocking position on F-actin. Myosin is then able to interact with F-actin and start its catalytic cycle (3, 4) .
The binding of Ca 2ϩ has strikingly different structural consequences in the regulatory N-lobes of cTnC and sTnC. In sTnC, the N-lobe switches from a ''closed'' (5, 6) to an ''open'' (7) (8) (9) conformation upon the binding of 2 Ca 2ϩ ions. Consequently, a hydrophobic pocket is exposed as the binding site for skeletal TnI (sTnI). This Ca 2ϩ -dependent structural transition was proposed by Herzberg, Moult, and James (ref. 10 , the so-called ''HMJ model'') and later confirmed by the crystal and NMR structures of sTnC (7) (8) (9) . By contrast, NMR studies have shown that the N-lobe of cTnC opens only partially upon the binding of a Ca ion is bound (see Fig. 2 B and C) . Thus TnC-based Ca 2ϩ regulation appears to have distinctive mechanisms in skeletal and cardiac muscles. Although the structures of sTnC, in both open and closed states, have been determined to high resolution by x-ray crystallography, no crystal structure of cTnC has previously been reported.
The essential role of cTnC in the regulation of contraction suggests that this protein is a logical target for drugs in the therapy of congestive heart failure. ''Calcium-sensitizers'' are a newly described class of inotropic drugs that enhance the responsiveness of the cardiac myofibril to calcium (14) . The effect of these agents on short-or long-term treatment of heart failure is uncertain. In fact, no agent has yet been developed that has high specificity as a calcium sensitizer of the thin filament. Several CaM antagonists bind directly to cTnC and are thus good model compounds for the design of calcium sensitizers (15) . For example, although bepridil (see Fig. 1B ) is not used clinically for congestive heart failure, this drug has been shown to increase both the Ca 2ϩ affinity of cTnC and the activity of actomyosin ATPase in vitro (16, 17) .
We have determined the crystal structure of 3Ca 2ϩ -cTnC complexed with bepridil to 2.15-Å resolution. Our results indicate that the calcium-sensitizing effect of bepridil arises from the stabilization of the fully open N-lobe by this drug. The current structure also reveals how the special properties of cTnC lead to a distinctive, stepwise mechanism for the opening of its N-lobe.
Materials and Methods
Crystallization and Data Collection. The A-Cys (C35S, C84S) mutant (18) of chicken cTnC studied here has the same functional properties as the wild-type protein. Orthorhombic (P2 1 2 1 2 1 ) crystals with unit cell dimensions a ϭ 36.27 Å, b ϭ 62.04 Å, c ϭ 62.04 Å were grown by vapor diffusion at 4°C from a mixture of 4 l of protein solution (1.2 mM cTnC͞6 mM CaCl 2 ͞2.5 mM bepridil⅐HCl͞10 mM Hepes, pH 7.2) and 4 l of reservoir buffer (30% PEG 3350͞20 mM MgCl 2 ͞50 mM Hepes, pH 7.2). The partial specific volume is 1.9 Å 3 ͞Da, with one molecule per asymmetric unit. Data were collected at 95 K to 2.15-Å resolution by using synchrotron radiation at the Cornell High Energy Synchrotron Source (CHESS; beamline A1, ϭ 0.935 Å). Data were reduced with the programs DENZO Structure Determination. A molecular replacement solution was obtained with the program AMORE (20), using the C-lobe of rabbit sTnC (8) and the 2Ca 2ϩ -bound N-lobe of avian sTnC (9) as independent search models, with data from 8.0-to 3.5-Å resolution. The final correlation coefficient was 38.8 (R factor 0.473). Positional refinement using the program XPLOR (21) (R factor 0.377, with data to 2.15 Å) yielded electron density maps (2͉F obs ͉ Ϫ ͉F calc ͉ and ͉F obs ͉ Ϫ ͉F calc ͉) which allowed manual rebuilding of the protein model with the program O (22) . Two bepridil molecules were also modeled into the electron density.
Subsequent maximum likelihood refinement and simulated annealing with the program CNSSOLVE (23) aided in the modeling of ordered waters and a third bepridil. Residues 1-4, 87-91, 125-126, and 161 are disordered and were not included in the final structure. Main-chain dihedral angles of all non-glycine residues lie in allowed regions of the Ramachandran plot, with 92.4% in most-favored regions.
Results and Discussion
Overall Description of the Structure. Bepridil-3Ca 2ϩ -cTnC displays a globular (46 ϫ 38 ϫ 35 Å) shape resembling that of CaMtrifluoperazine (TFP) and CaM-peptide complexes (Fig. 1A ) (24) (25) (26) . The central helical linker is unwound at residues 87-91, producing a 108°bend that brings the lobes close together. The two lobes are related by pseudo-twofold symmetry so that their hydrophobic pockets merge to form a channel largely occupied by two bepridil molecules (Bep1 and Bep2). A third bepridil (Bep3) is located at one end of the hydrophobic channel, near the N-terminal linker and helices B, C, and E, and partially blocks solvent access to the interior of the molecule. The structure contains 3 Ca 2ϩ ions, bound to domains II, III, and IV. Despite the absence of Ca 2ϩ in domain I, the N-lobe of the current structure reveals a strong similarity to the 2 Ca Bepridil-Induced Changes in the N-Lobe. The most important effect of bepridil on 3Ca 2ϩ -cTnC is the full opening of the N-lobe. No crystal structure is presently available for 3Ca 2ϩ -cTnC, so that our analysis relies on the comparison between the current structure and the NMR structure of the N-lobe of chicken 3Ca 2ϩ -cTnC (11) . In that study, the N-lobe hydrophobic pocket of 3Ca 2ϩ -cTnC (without bepridil) is largely unexposed, in contrast to that of 4Ca 2ϩ -sTnC. In the current study, upon the binding of bepridil, the A-B and C-D interhelical angles decrease from 138°and 108°to 92°and 89°, respectively. The N-lobe opens as helices B and C move as a pair away from helices A and D (Fig. 2 B and D) so that this bepridil-induced transition in cTnC resembles the Ca 2ϩ -induced transition in the N-lobe of sTnC (5-9).
As in sTnC (7) (8) (9) , the opening of the N-lobe in cTnC is accompanied by a backbone rearrangement in helix B, although domain I of cTnC is nonfunctional (Fig. 3) . In the solution study of the partially open N-lobe of 3Ca 2ϩ -cTnC (11), helix B displays a kink in its N-terminal region (residues 37-40) (Fig. 3A) . By contrast, in the current structure, residues 37-40 adopt a helical conformation, and the C terminus of helix B is swung away from helix A (Fig. 3B) . Several changes lead to the straightening of helix B upon the binding of bepridil. In the small ␤-sheet between domains I and II, the Thr 38 N-Gly The two N-lobe domains of cTnC, like those of sTnC (8, 9) , are structurally coupled through the small ␤-sheet. The breaking of the 38 N⅐⅐⅐⅐ 70 O hydrogen bond in the ␤-sheet not only contributes to the straightening of helix B but also releases the conformational constraints on Gly 70 and Thr 71 in the middle of Ca 2ϩ -binding loop II. Changes in the -angles of these two residues then allow helix C to move in a concerted fashion with helix B. As a result, the C-D interhelical angle in bepridil-3Ca 2ϩ -cTnC is smaller than that in 3Ca 2ϩ -cTnC.
Binding Sites for Bepridil. Bep1 plays the key role in the stabilization of the open N-lobe. Its phenyl group is located at the bottom of the N-lobe pocket in a small hydrophobic ''cavity'' (see Table 2 ) that seems to be the primary anchoring site for this drug molecule. Similar cavities have been found in CaM and accommodate certain bulky groups of several drugs (e.g., the trifluoromethyl group of TFP) (24, 25, 28) . The benzyl group of Bep1 protrudes toward the N-terminal linker and has extensive van der Waals contacts with helices B and C. The two aromatic rings of Bep1 are inserted as a ''wedge'' between the A-D and B-C units, sterically hindering the closing of the N-lobe (Fig. 2D) . Overall, Bep1 interacts with 13 hydrophobic residues in the N-lobe (Table  2 ) and shields 96 Å 2 of N-lobe apolar surface from the solvent (calculated with Insight '95, Molecular Simulations, Waltham, MA).
Bep2 and Bep3 appear to mimic the binding of TnI to the C-lobe. An overlay of the current structure and that of rabbit sTnC bound to the sTnI 1-47 fragment (29) shows that the phenyl ring of Bep2 takes the place of the side chain of Met 21 of sTnI (equivalent to Met 53 of cTnI) in the small hydrophobic cavity at the bottom of the C-lobe (see Table 2 and Fig. 4A ). Correspondingly, the binding of Bep2 results in a bend in helix F at Ile 119 , 29 for numbering scheme) occupies the position of Phe 122 of sTnC and has contacts with both the phenyl and benzyl groups of Bep2. Bep3 makes contacts with several residues on helix E (Table 2 ), which have also been shown to interact with TnI (29) . In fact, both bepridil and cTnI induce backbone conformational changes in the C terminus of helix F and the F-G linker (30) . Because Bep2 and Bep3 occupy the same region of the C-lobe as TnI, it appears that these two molecules probably would not bind to cTnC in the troponin complex. By contrast, Bep1 is not likely to be displaced by TnI (see below).
The compact shape of the current structure seems to be a direct result of drug binding. The positively charged pyrrolidine groups of the bepridils bring the N-and C-lobes close together by neutralizing the negative charges at their interface. Moreover, bepridil bridges the lobes through two ionic pairs: one between Bep1 pyrrolidine and Glu 96 (Fig. 1C) and the other between Bep3 pyrrolidine and Asp
99
. A similar effect on CaM has been observed for the inhibitor TFP, whose positively charged piperazine ring stabilizes a compact conformation in CaM (24, 25) . It has also been suggested that CaM cannot bind to its target proteins in this compact form (24) . By contrast, cTnC, when bound to the N-terminal region of cTnI (residues 33-80), adopts a more extended conformation than that of bepridil-3Ca 2ϩ -cTnC and CaM-TFP (31). Correspondingly, as noted above, bepridil appears to activate rather than inhibit cTnC.
Stepwise Mechanism for the Opening of the N-Lobe of cTnC. Previous NMR studies have shown that the 2Ca 2ϩ , 3Ca 2ϩ , and cTnI 147-163-bound states of cTnC assume three distinct conformations (11) (12) (13) . A comparison of these results with the current structure and with the crystal structures of sTnC (5, 6, 8, 9) reveals the details of a stepwise mechanism for the opening of the N-lobe of cTnC. In sTnC, the interhelical angles of domains I and II, which define the ''openness'' of the N-lobe, depend on the conformation of three groups of ''hinge residues'': Phe 29 all display nonhelical torsion angles (Fig. 2 A) (12) , and the small ␤-sheet is stabilized by four Fig. 1 . The overall structure of bepridil-3Ca 2ϩ -cTnC. (A) Stereo view of bepridil-3Ca 2ϩ -cTnC. cTnC comprises an N-and a C-terminal lobe. Each lobe consists of two helix-loop-helix EF-hand domains connected by a linker. The nomenclature is as follows: domain I (red) starts with helix A, followed by loop I, then helix B followed by the N-terminal linker (cyan); domain II (green) starts with helix C, followed by loop II, then helix D followed by the central linker (not included in the current structure because of disorder); domain III (yellow) starts with helix E, followed by loop III, then helix F followed by the C-terminal linker (purple and discontinuous at residues 125-126 because of disorder); domain IV (blue) starts with helix G, followed by loop IV, then helix H. There is also a helix N (black) N-terminal to domain I, which is present in TnC but not in CaM. There are two small antiparallel ␤-sheets in cTnC: one between loops I and II, and the other between loops III and IV. Three Ca 2ϩ ions, bound to domains II, III, and IV, are shown as orange spheres. Three bepridil molecules (balls and sticks) are bound to cTnC: Bep1 mainly to the N-lobe, Bep2 mainly to the C-lobe, and Bep3 to both lobes. In summary, the lengthening of helices A, B, and C is required for the full opening of the N-lobe in both sTnC (7) (8) (9) 27 ) and cTnC (11) (12) (13) . In both cases, however, the lengthening of helix B (which has the longest hinge region) produces the largest increase in the hydrophobic surface area of the lobe. As mentioned earlier, in sTnC the change in helix B requires the movement of a glutamate side chain toward the Ca 2ϩ ion in domain I (27) . By contrast, helix B of cTnC cannot be extended in such a fashion because domain I of this isoform does not bind Ca 2ϩ . Moreover, in cTnC the binding of a single Ca 2ϩ ion to domain II introduces relatively minor changes (11, 12) , which, as described above, are nonetheless essential for ''priming'' the opening of the N-lobe. As shown in the NMR study by Li et al. (13) and in the current work, the lengthening of helix B and the subsequent opening of the N-lobe are achieved by an agent such as cTnI or bepridil, which shields the N-lobe hydrophobic pocket from the solvent. This two-stage mechanism provides an extension to the HMJ model for sTnC (10) , in which the N-lobe opens upon the binding of two Ca 2ϩ ions.
Structural Basis for the Calcium-Sensitizing Effect of Bepridil. It is now clear how bepridil might increase the contractile force of the cardiac myofilament (17) . Biochemical studies have indicated that bepridil increases the Ca 2ϩ affinity of cTnC (16, 17) . From our results, it is apparent that bepridil hinders the closing of the N-lobe, a step that accompanies the release of Ca 2ϩ from domain II. The resultant increased Ca would not be displaced by cTnI. This prediction appears to be correct. In the current structure, Bep1 is in close contact with these three methionines (Table 2) . Moreover, an overlay of bepridil-3Ca 2ϩ -cTnC and 3Ca 2ϩ -cTnC-cTnI 147-163 (13) indicates that Bep1 and cTnI [147] [148] [149] [150] [151] [152] [153] [154] [155] [156] [157] [158] [159] [160] [161] [162] [163] bind to different regions of the hydrophobic core of the N-lobe: the former to the bottom of the N-lobe pocket, and the latter mainly to the apolar surfaces of helices A and B (Fig. 4B) . Due to the predicted displacement of Bep2 and Bep3 by TnI, it appears that the Ca 2ϩ -sensitizing effect of the drug resides in Bep1 alone.
Implications for the Future Design of Calcium-Sensitizing Agents for cTnC. Bepridil belongs to a group of pharmacological agents that also inhibit CaM from binding to its target proteins (34) . Most of these drugs have a large apolar region and a positively charged group at least 3 atoms away (25, 35) . The apolar region seems to be essential for the binding of these agents to the hydrophobic pockets of both cTnC and CaM. By contrast, the positively charged group is probably not required for cTnC-specific drugs, since the pyrrolidine ring of bepridil does not contribute to the opening of the N-lobe in the current structure. In fact, such a group, when bound to the N-lobe, might hinder the binding of the positively charged cTnI to cTnC. Moreover, because of the structural homology between cTnC and CaM, several drugs that bind to cTnC, including bepridil and TFP, have been shown to bind to CaM as well (13) . As noted above, such drugs with positively charged groups may trap CaM in an inactive form. To avoid such an inhibitory effect on CaM, neutral agents resembling bepridil could be designed to modulate the activity of cTnC. Although bepridil itself, as described earlier, is not a good pharmacological agent for heart failure, the current study provides insights into the features that may be important for the design of cTnC-specific calcium-sensitizers. Bep1  N-lobe  F27, I36, L41, V44, M45, L48, M60, I61, V64, V72,  F77, M80, M81, S84  C-lobe  E96, L97, L100  Bep2  N-lobe  F20, A23, I26, F27, F77, M81  C-lobe  L100, F104, I112, L117, M120, L136, F153, F156,  M157  Bep3 N-lobe M45, M50, P52, E56, M60 C-lobe E96, D99, L100, R102, M103
Residues whose side chains form the hydrophobic ''cavity'' at the bottom of each lobe are underlined. Residues that form salt bridges with the pyrrolidine rings of the bepridils are in boldface. (29) shows that Bep2 (dark red) mimics the binding of TnI (light green) to the C-lobe. Most notably, the pyrrolidine and phenyl groups of Bep2 occupy the same sites as the side chains of Lys 18 and Met 21 of sTnI (light green balls and sticks), respectively. (B) By contrast, Bep1 (dark red) and cTnI (sky blue) bind to different regions of the N-lobe pocket, as shown in the overlay of the N-lobes of bepridil-3Ca 2ϩ -cTnC (red) and 3Ca 2ϩ -cTnC-cTnI147-163 (blue) (13) .
